Scarica l'app Stockscreener
4.635
6.44%
-0.335
Passage Bio Inc Borsa (PASG) Ultime notizie
Passage Bio Announces Major Workforce Reduction and Restructuring - TipRanks
Passage Bio (NASDAQ: PASG) slashes workforce by 75% in 2026 restructuring - Stock Titan
Passage Bio Reports Trial Data, Reviews Strategic Options - MyChesCo
Chardan Capital Maintains Passage Bio (PASG) Buy Recommendation - MSN
Canaccord Genuity Remains a Buy on Passage Bio (PASG) - The Globe and Mail
PASG Maintains Rating by Oppenheimer -- Price Target Lowered to $15 - GuruFocus
PASG Downgraded by Chardan Capital -- Price Target Lowered to $7 - GuruFocus
Passage Bio (PASG) Downgraded by Wedbush Analyst - GuruFocus
PASG Downgraded by TD Cowen -- Rating Changed to Hold - GuruFocus
Passage Bio Faces Tougher FDA Road After Trial Shift, Wedbush Says - marketscreener.com
PASG Downgraded by Wedbush -- Price Target Lowered to $8.00 - GuruFocus
Passage Bio Seen as Undervalued Despite FDA Setback, Oppenheimer Says - marketscreener.com
Passage Bio downgraded to Neutral from Buy at Chardan - TipRanks
This Mohawk Industries Analyst Is No Longer Bullish; Here Are Top 2 Downgrades For Tuesday - Benzinga
Passage Bio stock rating cut to Hold by TD Cowen on FDA trial news - Investing.com South Africa
Oppenheimer Adjusts Price Target on Passage Bio to $15 From $30, Maintains Outperform Rating - marketscreener.com
Wedbush Downgrades Passage Bio to Neutral From Outperform, Cuts Price Target to $8 From $32 - marketscreener.com
Oppenheimer cuts Passage Bio stock price target on regulatory setback - Investing.com
Oppenheimer cuts Passage Bio stock price target on regulatory setback By Investing.com - Investing.com Australia
Passage Bio Announces PBFT02 Data and Strategic Review - The Globe and Mail
Chardan Downgrades Passage Bio to Neutral From Buy, Cuts Price Target to $7 From $21 - marketscreener.com
Chardan downgrades Passage Bio stock rating on strategic review By Investing.com - Investing.com South Africa
Chardan downgrades Passage Bio stock rating on strategic review - Investing.com
Passage Bio to Present at H.C. Wainwright Global Investment Conference - MSN
Wedbush Maintains Passage Bio(PASG.US) With Buy Rating, Maintains Target Price $32 - Moomoo
New Developments for Passage Bio (PASG) in Frontotemporal Dement - GuruFocus
Is Passage Bio (PASG) stock safe today (Underperforming) 2026-04-20Viral Momentum Stocks - Xã Thanh Hà
Lucid downgrades Passage Bio stock rating on funding concerns By Investing.com - Investing.com South Africa
Lucid downgrades Passage Bio stock rating on funding concerns - Investing.com
Passage Bio Starts Strategic Review After FDA Doesn't Support Single-Arm Trial - Moomoo
Passage Bio Reports Positive Interim Data for PBFT02 in FTD-GRN, Initiates Strategic Review After FDA Guidance 1 - Minichart
Passage Bio reports biomarker improvements in FTD trial - Investing.com
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Passage Bio reports biomarker improvements in FTD trial By Investing.com - Investing.com Canada
Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates - The Manila Times
Gene therapy company Passage Bio, Inc. recently disclosed two major decisions: the official appointment of Wedbush Pacgrow as its financial advisor, and the commencement of a comprehensive evaluation of strategic alternatives. - Bitget
Strategic review at Passage Bio (NASDAQ: PASG) after FDA trial guidance - Stock Titan
Leading Companies Fueling Innovation and Growth in the GM1 Gangliosidosis Market - openPR.com
Short Squeeze: What is the earnings history of Passage Bio IncTrade Entry Report & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
PMN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Trends in Growth, Segment Analysis, and Competitive Strategies Influencing the Adeno-Associated Viral Vectors Market - openPR.com
PASG PE Ratio & Valuation, Is PASG Overvalued - Intellectia AI
0.83%
0.61%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):